

T₃ Augmentation in Major Depressive Disorder: Safety Considerations

Lisa J. Rosenthal, M.D.; Whitney S. Goldner, M.D.; John P. O'Reardon, M.D.

From the Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago; the Department of Psychiatry, University of Pennsylvania, Philadelphia; and the Department of Medicine, University of Nebraska Medical Center, Omaha.

Received March 9, 2010; revision received Jan. 7, 2011; accepted Jan. 31, 2011.

Dr. O'Reardon has received research support or speaking or consulting fees from AstraZeneca, Bristol-Myers Squibb, CenRx Biopharma, Cyberonics, Eli Lilly, IC Axon, Magstim, Medtronic, and Neuronetics. Drs. Rosenthal and Goldner report no financial relationships with commercial interests.

From the Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago; the Department of Psychiatry, University of Pennsylvania, Philadelphia; and the Department of Medicine, University of Nebraska Medical Center, Omaha.

Address correspondence to Dr. Rosenthal (lrosenth@nmff.org).

Received March 9, 2010; Revised January 7, 2011; Accepted January 31, 2011.

Copyright © American Psychiatric Association

Am J Psychiatry 2011;168:1035-1040. doi:10.1176/appi.ajp.2011.10030402

Many cases of major depression are difficult to treat, and effective options are an urgent priority. Triiodothyronine (T₃) has been used to augment or accelerate treatment of major depression, and while there is good evidence for its efficacy in the short term, there is a limited evidence base to guide long-term adjunctive use. In a collaborative case from the endocrinology and psychiatry perspectives, we review the evidence for the safety of this intervention. A case presentation from our clinical practice is used to illustrate issues of efficacy, adherence, and use in the setting of medical comorbidity, and suggested guidelines are presented for monitoring the safety of T₃ when used as longer-term augmentation.

Mechanism of Action of T₃ Augmentation

Abnormalities of thyroid regulation have been detected in many patients with depressive syndromes. Patients with major depression appear to have a higher incidence of subclinical thyroid abnormalities (1), and it is clear that diseases of the thyroid can have a profound effect on mood.

Thyroid hormone is important for protein synthesis and metabolism for virtually every organ, including the brain. The release of thyroid-stimulating hormone (TSH) from the anterior pituitary is regulated by thyroid-releasing hormone (TRH) from the hypothalamus. TSH in turn prompts the release of mainly levothyroxine (T₄), and to a lesser extent T₃, from the thyroid gland; T₄ is considered a "prohormone" with very little intrinsic activity and is transformed in the peripheral tissues into T₃, the biologically active form of thyroid hormone. Through negative feedback, pituitary TSH levels are regulated by the serum free T₄ and free T₃, and even subtle changes often lead to substantial changes in TSH levels, making TSH a particularly useful screening test for hypothalamic-pituitary-thyroid (HPT) axis function (2).

T₃ acts in the cell nucleus, stimulating gene expression and energy metabolism in cells in every organ and potentially enhancing neurogenesis in the CNS (2). T₃, both alone and in combination with fluoxetine, modulates gene transcription, with changes in mRNA coding for the 5-HT_{1A} and 5-HT_{1B} receptors (3). In the CNS, T₄ conversion to T₃ occurs intracellularly, which may be why T₃ administration seems to have particular benefit in the treatment of affective disorders (4). The enzymes

responsible for the conversion of T_4 to T_3 are also different in the CNS, perhaps explaining individual responses to T_3 supplementation and the variability of symptoms in subclinical hypothyroidism. Cooper-Kazaz et al. (5) have demonstrated that genetic polymorphisms in the type 1 deiodinase (DIO1) gene, which assists in the conversion of T_4 to T_3 , might help determine which patients will respond to T_3 augmentation.

It is also possible that T_3 acts directly as a neurotransmitter or that it directly influences neurotransmission through monoamines (3). Actions at noradrenergic, serotonergic, and beta-adrenergic neurons have all been demonstrated, largely through studies of hypo- and hyperthyroid states. Rodent studies have demonstrated serotonergic effects of T_3 and T_4 , supporting the idea that serotonergic transmission is enhanced by normal thyroid functioning, potentially through desensitization of the 5-HT_{1A} autoreceptor (6). T_3 was initially thought to be active solely within the noradrenergic projection pathway, and it may serve as a co-transmitter with norepinephrine in the limbic system, but it has also been demonstrated in high concentrations in the serotonergic raphe nuclei and their projections (7).

Evidence Base for Thyroid Augmentation

T_3 in Conjunction With Tricyclic Antidepressants

Augmentation of antidepressants with T_3 is one of the oldest evidence-based treatments for major depressive disorder. In 1969, Prange et al. conducted a pivotal study (8) demonstrating that administration of liothyronine enhanced response to tricyclic antidepressants in patients with treatment-resistant depression. Thyroid function was monitored, but methods available at that time were not sensitive or specific. Based on ankle jerk reflexes and protein-bound iodine assays, patients in the study appeared to have elevated thyroid function after treatment. Many subsequent studies have confirmed the Prange et al. study's finding of efficacy, but few have formally assessed the HPT axis during treatment.

The majority of the evidence base for use of T_3 is for its coadministration with tricyclics. Two meta-analyses of T_3 coadministration with tricyclics have been published, one reviewing acceleration trials (9) and the other augmentation trials (10). Acceleration is defined as the use of T_3 at commencement of antidepressant treatment to enhance and hasten response. Augmentation is the administration of T_3 in patients who are unresponsive or partially responsive to an adequate course of antidepressant treatment initiated previously.

Acceleration of antidepressant response with T_3 .

A meta-analysis by Altshuler et al. (9) of six double-blind, placebo-controlled studies (125 patients total) of T_3 acceleration of tricyclics was positive. By definition, these were short-term studies of 2 to 3 weeks, and none discussed the option of continuing T_3 once antidepressant response was achieved. In addition, many were conducted before the advent of more sensitive assays of thyroid functioning in the late 1980s. Three of these acceleration studies (11–13) obtained initial lab values of protein-bound iodine and looked at ankle jerk reflexes and serum T_4 binding, but none performed follow-up testing. No differences in baseline thyroid tests were found between patients who responded to T_3 and those who did not, but some authors speculated that there may have been subtle thyroid dysfunction in the responders that was undetectable by the assays. In addition, a significant gender effect was observed, with women responding more robustly than men. While women generally have been found to have higher rates of both comorbid depressive syndromes and thyroid disease, a consistent association has not been replicated.

Augmentation of antidepressant response with T_3 .

Aronson et al. (10) conducted a positive meta-analysis of T_3 augmentation of tricyclics, finding eight controlled clinical studies with 292 patients. The studies were up to 12 weeks long, and several performed baseline and follow-up modern thyroid assays (4, 14–16). One positive study in 1977 conducted initial thyroid screening and additionally tested the CSF monoamine metabolites 5-hydroxyindoleacetic acid and homovanillic acid, hypothesizing that the mechanism of treatment with T_3 was an increase of available monoamines (17). However, the study found no differences in CSF monoamine metabolites between the placebo and active T_3 groups or between responders and nonresponders to T_3 .

Thase et al. (14) found no association between results of thyroid function tests or TRH stimulation testing at baseline and outcome in a subset of patients treated with T_3 . Joffe and Singer (4) evaluated T_3 versus T_4 in a randomized trial and found significant changes after 3 weeks in T_3 , T_4 , free T_4 , TSH, and T_3 resin uptake in both groups, but these changes were not positive predictors of response; the main finding was that T_3 was more effective than T_4 as an augmenter. A 2-week augmentation study of lithium and T_3 (15) found in 1993 that the two were equally effective and outperformed placebo, with baseline TSH documented as being within normal range.

T_3 in Conjunction With SSRIs

Recently a number of studies have examined the augmentation of selective serotonin reuptake inhibitors (SSRIs) with thyroid hormone, but the data are more limited than with tricyclics. A review by Cooper-Kazaz and Lerer (18) found that not enough data were available yet for a meta-analysis but that a positive trend was revealed when the available double- and single-blind studies were analyzed. Papakostas et al. (19) reported a negative meta-analysis using strict inclusion criteria and finding only three adequate double-blind, randomized, placebo-controlled studies. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (20) evaluated SSRI augmentation using either lithium or T_3 and found no statistical difference in efficacy between the treatments, but T_3 had superior tolerability and adherence. All of these studies were short term, with the longest (STAR*D) lasting 12 weeks.

Two studies of T_3 in combination with SSRIs included baseline and follow-up thyroid testing. In the first, Cooper-Kazaz et al. (21) compared sertraline (50–100 mg) combined with either T_3 (25–35 μ g) or placebo in an 8-week study and found that the sertraline- T_3 combination produced superior response and remission rates. After 8 weeks of T_3 supplementation, the mean TSH level fell significantly from 1.70 μ IU/ml at baseline to 0.28 μ IU/ml in responders, whereas nonresponders had mean pre- and posttreatment levels of 1.88 μ IU/ml and 0.76 μ IU/ml, respectively; responsiveness to treatment was significantly correlated ($p=0.01$) with the change in TSH level, suggesting that the therapeutic benefit could have been due to changes in the thyroid axis in this population. In a post hoc analysis, baseline T_3 levels in patients who responded to T_3 augmentation were significantly lower than in those who did not respond (107.60 ng/dl compared with 137.4 ng/dl, $p=0.002$). There was also a small but significant decline in TSH levels in the placebo group.

A combination study by Appelhof et al. (22) in which 124 patients were randomly assigned to receive paroxetine combined with 25 μ g of T_3 , 50 μ g of T_3 , or placebo showed a statistically significant dose-dependent increase of T_3 levels along with lowered T_4 (the final T_4 levels after 8 weeks of treatment were 0.9 pmol/liter in the placebo group, 0.6 pmol/liter in the 25- μ g T_3 group, and 0.4 pmol/liter in the 50- μ g T_3 group). Significant changes in thyroid function on testing were associated with significant side effects in nine of 28 patients in the 50- μ g group, including sweating, tremor, nervousness, and palpitations, but there were no significant differences between the 25- μ g T_3 and placebo groups. It is possible that noradrenergic effects of paroxetine due to norepinephrine transporter blockade exacerbated somatic symptoms that were consistent with a hyperthyroid state. Efficacy outcome was negative, with no differences between placebo and the two T_3 groups.

While T_3 compared well with lithium in STAR*D (20), and results with T_3 as an augmentation or combination strategy are encouraging, more controlled trials are needed to fully determine the efficacy of T_3 in combination with SSRIs.

Safety in Longer-Term Studies

In a study of pre- and postmenopausal women on high-dosage T_4 (not T_3) for bipolar disorder or major depressive disorder, Gyulai et al. (23) found no significant differences in bone density after at least 1 year of treatment (with several patients having up to 5 years of treatment), but they noted a nonsignificantly greater decline in bone density in postmenopausal women. Prior to follow-up scanning for bone density, the mean TSH level on high dosages of T_4 (300–500 $\mu\text{g/day}$) was normal at 0.4 $\mu\text{IU/ml}$. Similarly, Kelly and Lieberman (24) administered up to 150 μg of T_3 daily to 14 patients for an average duration of 24 months, and no cardiac or skeletal sequelae were detected.

Safety: The Perspective From Endocrinology

There is no consensus in endocrinology on use of thyroid hormone for the treatment of depression in euthyroid patients. When treating patients with hypothyroidism, endocrinology guidelines generally recommend using T_4 monotherapy (25). Multiple studies, including a meta-analysis, have evaluated the difference between T_4 monotherapy and T_3/T_4 combination therapy for the treatment of hypothyroidism. Overall no meaningful statistical differences have been found between the two regimens (26–31). Nevertheless, some studies have reported patient preference for combination therapy that was not explained by symptom outcomes, neurocognitive changes, or quality-of-life assessments (27). In one study (28), 44% of the patients reporting a preference for combination therapy had a suppressed TSH level, suggesting overreplacement of thyroid hormone. A study from Denmark (32) evaluated T_4 monotherapy compared with combination T_3/T_4 therapy while maintaining equivalent TSH values. Quality-of-life scores and depression and anxiety rating scores were significantly better in seven of 11 categories with combined therapy compared with monotherapy, and 49% of patients preferred combination T_4/T_3 therapy, compared with 15% who preferred T_4 monotherapy.

In euthyroid patients, high T_3 dosages carry a higher risk of induction of hyperthyroidism. In this respect, preexisting hypertension, tachycardia, and hyperglycemia could all potentially be worsened by hyperthyroidism (33). Subclinical hyperthyroidism has also been associated with long-term side effects, including reduced bone mineral density and an increased risk of osteoporosis, especially in postmenopausal women (34, 35), and an increased risk of atrial arrhythmias (36). Thus, when thyroid hormones are used in treating depression, clinicians should closely monitor patients for biochemical or clinical evidence of hyperthyroidism.

Ideally, patients who are started on T_3 augmentation for a psychiatric disorder should be monitored in the same manner as patients with hypothyroidism. TSH, free T_4 , and free T_3 levels should be measured regularly, as well as whenever there is a report of increased anxiety, tremor, palpitations, insomnia, or other symptoms suggestive of hyperthyroidism. Patients should also be monitored for other conditions that could be exacerbated by T_3 supplementation, including hypertension, tachycardia, osteopenia or osteoporosis, atrial arrhythmias, and hyperglycemia. Finally, it should be borne in mind that some beta-blockers influence thyroid hormone metabolism and plasma levels (37).

Conclusions and Recommendations

Pharmacologic augmentation strategies currently approved by the U.S. Food and Drug Administration for major depressive disorder are limited to the second-generation antipsychotics aripiprazole and quetiapine, both of which are associated with safety concerns in long-term use. Lithium is another guideline-recommended agent, but it does not have a better tolerability profile than T_3 . Current textbooks and the 2010 APA guidelines (38) agree that there is good evidence for the use of T_3 in depressive syndromes, but largely do not mention monitoring of thyroid functioning. Schatzberg et al. (39) suggest use of T_3 in postmenopausal women or atypical depression and tapering augmentation after 60 days.

There is good evidence to suggest that T_3 administration is helpful in the treatment of depressive states, but only limited data are available on long-term safety. Few of the randomized controlled studies of T_3 included both initial and follow-up thyroid function testing; those that did such testing showed expected changes in the thyroid axis and were largely reassuring on the

issue of significant side effects. Many psychiatrists are nevertheless uncomfortable prescribing thyroid hormones to essentially euthyroid patients, and some of our colleagues in endocrinology may also find this practice controversial.

In clinical decision making, the risk to health and safety from partially or inadequately treated major depression must be weighed against any putative risks of treatment. Findings from the STAR*D effectiveness trials (40) and from a meta-analysis (41) have highlighted shortcomings in the efficacy of antidepressants, which reinforces the need for psychiatrists to be flexible and creative in crafting their pharmacotherapy interventions for many patients suffering with major depression. The clinical case presented here highlights the morbidity from persistent depression in one patient in whom, for metabolic reasons, other augmentation strategies were considered high risk. In the case of T₃ augmentation, based on the literature and our clinical experience, we would recommend the safety guidelines summarized in [Figure 1](#).

FIGURE 1.

Recommended Safety Guidelines for T₃ Augmentation of Antidepressant Medication

1. Obtain baseline TSH, free T_4 , and free T_3 levels prior to augmentation.
2. Recheck thyroid indices at 3 months and then every 6 months, or at minimum annually. The goal is for the TSH level to be at least at the lower limit of the normal range (around 0.4 $\mu\text{U}/\text{mL}$) or below in the absence of hyperthyroid symptoms. Free T_3 level can be maintained at the upper limit of the normal range based on the severity of depressive symptoms and response to T_3 .
3. In the longer term, if the patient has a history of multiple episodes or significant treatment resistance, maintenance on T_3 is reasonable as an open-ended treatment option. If there are no symptoms of hyperthyroidism and no known cardiac disease, consider maintenance T_3 supplementation even if the TSH level is below the normal reference range, depending on clinical efficacy.
4. Document a discussion of the risk-benefit profile of long-term T_3 augmentation, including potential cardiac and bone disease risk.
5. In postmenopausal women, bone density should be monitored with densitometry every 2 years. If bone density is declining, referral for evaluation of osteoporosis should be made. Standard recommendations for all postmenopausal women also include calcium (1200 mg/day) and vitamin D (800–1000 IU/day) supplementation.
6. Periodically reevaluate the risks and benefits of T_3 supplementation, focusing specifically on depressive symptoms or change in status of cardiovascular disease.

1. Obtain baseline TSH, free T₄, and free T₃ levels prior to augmentation.
2. Recheck thyroid indices at 3 months and then every 6 months, or at minimum annually. The goal is for the TSH level to be at least at the lower limit of the normal range (around 0.4 μ IU/ml) or below in the absence of hyperthyroid symptoms. Free T₃ level can be maintained at the upper limit of the normal range based on the severity of depressive symptoms and response to T₃.
3. In the longer term, if the patient has a history of multiple episodes or significant treatment resistance, maintenance on T₃ is reasonable as an open-ended treatment option. If there are no symptoms of hyperthyroidism and no known cardiac disease, consider maintenance T₃ supplementation even if the TSH level is below the normal reference range, depending on clinical efficacy.
4. Document a discussion of the risk-benefit profile of long-term T₃ augmentation, including potential cardiac and bone disease risk.
5. In postmenopausal women, bone density should be monitored with densitometry every 2 years. If bone density is declining, referral for evaluation of osteoporosis should be made. Standard recommendations for all postmenopausal women also include calcium (1200 mg/day) and vitamin D (800–1000 IU / day) supplementation.
6. Periodically reevaluate the risks and benefits of T₃ supplementation, focusing specifically on depressive symptoms or change in status of cardiovascular disease.

References

- 1
Arem R; Cusi K: Thyroid function testing in psychiatric illness: usefulness and limitations. Trends Endocrinol Metab 1997; 8:282–287
[\[PubMed\]](#)
[\[CrossRef\]](#)
- 2
Wilson JD; Foster DW (eds): Williams Textbook of Endocrinology, 8th ed. Philadelphia, WB Saunders, 1992
- 3
Lifschytz T; Segman R; Shalom G; Lerer B; Gur E; Golzer T; Newman ME: Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 2006; 7:203–210
[\[PubMed\]](#)
[\[CrossRef\]](#)
- 4
Joffe RT; Singer W: A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990; 32:241–251
[\[PubMed\]](#)
[\[CrossRef\]](#)
- 5
Cooper-Kazaz R; van der Deure WM; Medici M; Visser TJ; Alkelai A; Glaser B; Peeters RP; Lerer B: Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord 2009; 116:113–116
[\[PubMed\]](#)
[\[CrossRef\]](#)
- 6
Gur E; Lerer B; Newman ME: Chronic clomipramine and triiodothyronine increase serotonin levels in rat frontal cortex in vivo: relationship to serotonin autoreceptor activity. J Pharmacol Exp Ther 1999; 288:81–87
[\[PubMed\]](#)
- 7
Bauer M; Heinz A; Whybrow PC: Thyroid hormones, serotonin, and mood: of synergy and significance in the adult brain. Mol Psychiatry 2002; 7:140–156
[\[PubMed\]](#)
[\[CrossRef\]](#)
- 8
Prange AJ Jr; Wilson IC; Rabon AM; Lipton MA: Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969; 126:457–469
[\[PubMed\]](#)
- 9

Altshuler LL; Bauer M; Frye MA; Gitlin MJ; Mintz J; Szuba MP; Leight KL; Whybrow PC: Does thyroid supplementation accelerate tricyclic antidepressant response? a review and meta-analysis of the literature. Am J Psychiatry 2001; 158:1617–1622

[\[PubMed\]](#)

[\[CrossRef\]](#)

10

Aronson R; Offman HJ; Joffe RT; Naylor CD: Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53:842–848

[\[PubMed\]](#)

[\[CrossRef\]](#)

11

Wheatley D: Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 1972; 26:229–233

[\[PubMed\]](#)

[\[CrossRef\]](#)

12

Coppen A; Whybrow PC; Noguera R; Maggs R; Prange AJ Jr: The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972; 26:234–241

[\[PubMed\]](#)

[\[CrossRef\]](#)

13

Feighner JP; King LJ; Schuckit MA; Croughan J; Briscoe W: Hormonal potentiation of imipramine and ECT in primary depression. Am J Psychiatry 1972; 128:1230–1238

[\[PubMed\]](#)

14

Thase ME; Kupfer DJ; Jarrett DB: Treatment of imipramine resistant recurrent depression, I: an open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989; 50:385–388

[\[PubMed\]](#)

15

Joffe RT; Singer W; Levitt AJ; MacDonald C: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387–393

[\[PubMed\]](#)

[\[CrossRef\]](#)

16

Gitlin MJ; Weiner H; Fairbanks L; Hershman JM; Friedfeld N: Failure of T₃ to potentiate tricyclic antidepressant response. J Affect Disord 1987; 13:267–272

[\[PubMed\]](#)

[\[CrossRef\]](#)

17

Banki CM: Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women. Eur J Clin Pharmacol 1977; 11:311–315

[\[PubMed\]](#)

[\[CrossRef\]](#)

18

Cooper-Kazaz R; Lerer B: Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. *Int J Neuropsychopharmacol* 2008; 11:685–699

[\[PubMed\]](#)

[\[CrossRef\]](#)

19

Papakostas GI; Cooper-

Kazaz R; Appelhof BC; Posternak MA; Johnson DP; Klibanski A; Lerer B; Fava M: Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. *Int Clin Psychopharmacol* 2009; 24:19–25

[\[PubMed\]](#)

[\[CrossRef\]](#)

20

Nierenberg AA; Fava M; Trivedi MH; Wisniewski SR; Thase ME; McGrath PJ; Alpert JE; Warden D; Luther JF; Niederehe G; Lebowitz B; Shores-Wilson K; Rush AJ; STAR*D Study Team: A comparison of lithium and T₃ augmentation following two failed medication treatments for depression: a STAR*D report. *Am J Psychiatry* 2006; 163:1519–1530

[\[PubMed\]](#)

[\[CrossRef\]](#)

21

Cooper-Kazaz R; Apter JT; Cohen R; Karagichev L; Muhammed-

Moussa S; Grupper D; Drori T; Newman ME; Sackeim HA; Glaser B; Lerer B: Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 2007; 64:679–688

[\[PubMed\]](#)

[\[CrossRef\]](#)

22

Appelhof BC; Brouwer JP; van

Dyck R; Fliers E; Hoogendijk WJ; Huyser J; Schene AH; Tijssen JG; Wiersinga WM: Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. *J Clin Endocrinol Metab* 2004; 89:6271–6276

[\[PubMed\]](#)

[\[CrossRef\]](#)

23

Gyulai L; Bauer M; Garcia-Espana F; Hierholzer J; Baumgartner A; Berghöfer A; Whybrow PC: Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. *J Affect Disord* 2001; 66:185–191

[\[PubMed\]](#)

[\[CrossRef\]](#)

24

Kelly TF; Lieberman DZ: Long term augmentation with T₃ in refractory major depression. J Affect Disord 2009; 115:230–233

[\[PubMed\]](#)

[\[CrossRef\]](#)

25

Baskin HJ; Cobin RH; Duick DS; Gharib H; Guttler RB; Kaplan MM; Segal RL; American Association of Clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8:457–469

[\[PubMed\]](#)

26

Clyde PW; Harari AE; Getka EJ; Shakir KM: Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 2003; 290:2952–2958

[\[PubMed\]](#)

[\[CrossRef\]](#)

27

Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sängler E; Engel G; Hamm AO; Nauck M; Meng W: Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004; 60:750–757

[\[PubMed\]](#)

[\[CrossRef\]](#)

28

Appelhof BC; Fliers E; Wekking EM; Schene AH; Huyser J; Tijssen JG; Endert E; van Weert HC; Wiersinga WM: Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90:2666–2674

[\[PubMed\]](#)

[\[CrossRef\]](#)

29

Escobar-Morreale HF; Botella-Carretero JJ; Gómez-Bueno M; Galán JM; Barrios V; Sancho J: Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005; 142:412–424

[\[PubMed\]](#)

30

Escobar-Morreale HF; Botella-Carretero JJ; Escobar del Rey F; Morreale de Escobar G: Review: treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab 2005; 90:4946–4954

[\[PubMed\]](#)

[\[CrossRef\]](#)

31

Ma C; Xie J; Huang X; Wang G; Wang Y; Wang X; Zuo S: Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl Med Commun 2009; 30:586–593

[\[PubMed\]](#)

[\[CrossRef\]](#)

32

Nygaard B; Jensen EW; Kvetny J; Jarløv A; Faber J: Effect of combination therapy with thyroxine (T₄) and 3,5,3-triiodothyronine (T₃) versus T₄ monotherapy in patients with hypothyroidism: a double blind, randomized cross-over study. *Eur J Endocrinol* 2009; 161:895–902

[\[PubMed\]](#)

[\[CrossRef\]](#)

33

Osei K; Falko JM; O'Dorisio TM; Adam DR: Decreased serum C-peptide/insulin molar ratios after oral glucose ingestion in hyperthyroid patients. *Diabetes Care* 1984; 7:471–475

[\[PubMed\]](#)

[\[CrossRef\]](#)

34

Uzzan B; Campos J; Cucherat M; Nony P; Boissel JP; Perret GY: Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. *J Clin Endocrinol Metab* 1996; 81:4278–4289

[\[PubMed\]](#)

[\[CrossRef\]](#)

35

Faber J; Galløe AM: Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. *Eur J Endocrinol* 1994; 130:350–356

[\[PubMed\]](#)

[\[CrossRef\]](#)

36

Cappola AR; Fried LP; Arnold AM; Danese MD; Kuller LH; Burke GL; Tracy RP; Ladenson PW: Thyroid status, cardiovascular risk, and mortality in older adults. *JAMA* 2006; 295:1033–1041

[\[PubMed\]](#)

[\[CrossRef\]](#)

37

Wiersinga WM: Propranolol and thyroid hormone metabolism. *Thyroid* 1991; 1:273–277

[\[PubMed\]](#)

[\[CrossRef\]](#)

38

American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 3rd ed. *Am J Psychiatry* 2010; 167(Octsuppl)

39

Schatzberg AF; Cole JO; DeBattista C: Augmentation strategies for treatment-resistant disorders, in *Manual of Clinical Psychopharmacology*, 7th ed. American Psychiatric Publishing, 2010, pp 500–544

40

Rush AJ; Trivedi MH; Wisniewski SR; Nierenberg AA; Stewart JW; Warden D; Niederehe G; Thase ME; Lavori PW; Lebowitz BD; McGrath PJ; Rosenbaum JF; Sackeim HA; Kupfer DJ; Luther J; Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905–1917

[\[PubMed\]](#)

[\[CrossRef\]](#)

41

Turner EH; Matthews AM; Linardatos E; Tell RA; Rosenthal R: Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358:252–260

[\[PubMed\]](#)

[\[CrossRef\]](#)

Copyright © American Psychiatric Association